Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Commercial-Stage Moderna Debuts At J.P. Morgan

Executive Summary

Moderna has received $2.8bn for advance purchase agreements for its COVID-19 vaccine, with much more to follow. Management outlined some initial financial updates for investors.

You may also be interested in...



Speculation Over Moderna Vaccine Deal With Tata, Wockhardt

Moderna is speculated to be in talks with Indian firms, including Wockhardt and a Tata group company, for manufacturing and/or marketing its COVID-19 vaccine. A deal in India could help the company meet its obligation to supply COVAX but Moderna is likely to choose its partner carefully.

J&J Forecasts Strong Pharma Growth In 2021, But No COVID-19 Vaccine Update

Data from a high-profile Phase III COVID-19 vaccine trial will be released the first week of February, management said.

J.P. Morgan, Without The Parties, Reveals An Industry Ready To Get Down To Business

The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC143605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel